There's a growing recognition that the molecular profile of a primary tumor can differ significantly from its metastases. To guide treatment more accurately, the preferred practice is to biopsy an accessible metastatic lesion when possible, as this better reflects the biology of the active disease being treated.

In ambiguous cases, immunohistochemistry showing the loss of the RB1 protein is a powerful indicator of a poorly differentiated neuroendocrine carcinoma (NEC). This helps distinguish NECs from high-grade neuroendocrine tumors or adenocarcinomas with neuroendocrine features, a critical distinction for prognosis and treatment.

In community SCLC care, molecular strategies are not monolithic. Genomic alteration testing (NGS) is ready for immediate use and can identify targets today. In contrast, neuroendocrine subtyping is still investigational and not yet clinically actionable, pending results from research studies.

The novel target DLL3 is a promising avenue for treating NECs, but its therapeutic efficacy is highly dependent on expression levels. Early trial data for a DLL3 T-cell engager showed a 40% response rate in high-expressing tumors versus just 3% in low-expressors, mandating biomarker testing for patient selection.

Despite widespread use in oncology, immunotherapy has limited efficacy in extrapulmonary NEC. Real-world data for combination CTLA-4 and PD-1 inhibitors show response rates around 15%, with sustained responses in less than 10% of patients. This highlights the urgent need for novel therapeutic approaches beyond checkpoint inhibition.

Contrary to common belief, HER2 can be expressed or amplified in prostate cancer, particularly in subtypes with neuroendocrine features. This creates a rare but actionable target, with reported complete responses to HER2-directed therapies like TDXD, highlighting the need for broader genomic testing.

Despite mutation testing being a critical first step for effective treatment planning in gastrointestinal stromal tumors (GIST), a significant number of patients in the United States still do not receive this essential diagnostic. This highlights a major gap between established best practices and real-world clinical application.

Unlike breast or lung cancer where a biomarker's effectiveness persists across treatment stages, biomarkers in upper GI cancers often fail to show similar efficacy when moved from one line of therapy to another. This suggests a more variable and rapidly changing tumor biology.

A patient's clinical history can override ambiguous histology. A high-grade neuroendocrine neoplasm in a patient with a prior well-differentiated NET is almost certainly a progressive G3 NET, not a poorly differentiated NEC, as the two tumor types follow distinct biological progression pathways.